In an article by Rachel Nielsentitled “Seattle Genetics’ ambitious plan for 12 more drugs, 100 more employees,” she writes about how Seattle Genetics is a formulating a treatment for Hodgkin lymphoma. The drug that is used to treat the lymphoma is called Adcetris, and it has already amassed 226 million dollars in sales in 2015, while being available to Canadian and American consumers. This year, it is expected to reach sales of up to 275 million dollars. The company is also researching and new drug that they call 33A, and it is expected to go into Phase 3 of its clinical trials this year. That drug will go onto treat myeloid leukemia. Along with those drugs, Seattle Genetics also is in the process of producing a drug that will help to treat breast cancer, and two other drugs for bladder cancer. The co-founder of Seattle Genetics, Clay Siegall, had this to say about the development of the drugs, “We’re going to put out this year a substantial amount of data.”
Seattle Genetics is also in the plans of hiring 100 new employees to its payroll, as it already has over 800 employees. Siegall says that Seattle Genetics’ offices have room for another 350 employees.
Clay Siegall co-founded Seattle Genetics back in 1998, and he is the current president for the company. He also has the roles of chief executive officer and chairman. He was trained as a scientist from The George Washington University, where he received his Ph.D. in Genetics.
Aside from his work at Seattle Genetics, he is also the director on the board of directors for Ultragenyx Pharmaceuticals, Mirna Therapeutics, and Alder Biopharmaceuticals. In 2012, Clay Siegall was award the Entrepreneur of the Year award from Pacific Northwest Ernst & Young, and he also received an award from the University of Maryland called “Alumnus of the Year for Computer, Math and Natural Sciences.”